Insmed Incorporated (INSM)

Over the past six months, Insmed's stock (INSM) has trended down by approximately 44.65%. On January 12, 2026, shares gained over 3% after the company reported preliminary sales for full-year 2025 that exceeded forecasts, and outlined expected milestones for 2026. On April 7, 2026, the stock experienced a decline following the announcement that its Phase 2b CEDAR study of brensocatib in hidradenitis suppurativa (HS) missed both primary and secondary endpoints, leading to the discontinuation of the HS program. On May 7, 2026, despite reporting first-quarter 2026 results that exceeded Wall Street's earnings and revenue estimates, Insmed's shares fell by 6.63% in pre-market trading. On May 8, 2026, an analyst from H.C. Wainwright identified the dip as a potential buying opportunity, citing a robust fundamental outlook for BRINSUPRI.

Based on the available information, there is no explicit indication of significant demand seasonality for Insmed, Inc.'s products and services. The company's therapies target serious and rare diseases, where patient demand is typically driven by medical need rather than seasonal factors.

Insmed, Inc. is a global biopharmaceutical company focused on developing and commercializing therapies for serious and rare diseases, operating within the Healthcare sector, specifically in the Biotechnology and Pharmaceutical industries. The company's business model focuses on addressing unmet medical needs in niche markets, particularly in severe respiratory and immunological conditions. Its primary commercial products include ARIKAYCE for Mycobacterium avium complex (MAC) lung disease and BRINSUPRI for non-cystic fibrosis bronchiectasis (NCFB). Insmed also has a diverse pipeline of investigational programs, including treprostinil palmitil inhalation powder (TPIP) for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), and INS1148, an investigational monoclonal antibody for respiratory and immunological and inflammatory diseases. Early-stage research spans technologies such as gene therapy and AI-driven protein engineering.

Insmed is headquartered in Bridgewater, New Jersey, United States, and maintains offices and research locations across the United States, Europe, and Japan. Its significant subsidiaries are primarily located in Europe and North America, which together host a substantial portion of its material entities. The United States is the primary source of revenue from the sale of its commercial products.

Insmed positions itself as a "people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases." The FDA approval of BRINSUPRI in August 2025 was a significant positive event, representing a first-in-class therapy. The strong U.S. launch of BRINSUPRI has also contributed positively to the company's perception. The clinical trial setback for brensocatib in hidradenitis suppurativa (HS) in April 2026 led to a stock price drop, but was primarily a pipeline disappointment.

Insmed's ownership is predominantly held by institutional investors, including JPMorgan Chase & Co, Vanguard Group Inc, and BlackRock, Inc. Richard S. Kollender is the largest individual Insmed shareholder, owning 21.92 million shares, representing 10.17% of the company.